688336.SS
Strong BuyUnloved QualitySunshine Guojian Pharmaceutical (Shanghai) Co., Ltd · Healthcare · China · $5.2B
CNY 41.43 +1.8% · close 30 Sep · scored 6 Oct
StockRank down 1.2 since 3 Oct: Momentum down 3.
Unloved Quality: Strong and cheap; the market has not turned yet.
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
ABOUT SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD
Read
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. focuses on the development, manufacturing, and commercialization of antibody therapeutics, with a strong presence in autoimmune and oncology treatments. Its flagship product, Yisaipu, was China's first marketed recombinant human TNF-alpha receptor fusion protein, establishing a strong first-mover advantage. The company is a vertically integrated biopharmaceutical leader with one of the largest antibody production capacities in China.
FINANCIAL SUMMARY (CNY)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 825.5M | 1.0B | 1.2B | 4.2B | 72.0% | 4.4B | 1.7B | 1.8B | -33.7% |
| EPS (CNY) | 0.06 | 0.33 | 0.79 | 3.24 | 288.7% | 3.43 | — | — | — |
| Shares | 894.3M | 894.3M | 894.3M | 894.3M | 0.0% | 896.2M | — | — | — |
| Debt | 150.1M | 50.0M | 50.0M | — | -42.3% | — | — | — | — |
| Equity | 4.6B | 4.9B | 5.6B | 8.5B | 22.4% | — | — | — | — |
| Op CF | 233.5M | 416.4M | 281.1M | 3.0B | 135.3% | 2.8B | — | — | — |
| Inv CF | -916.7M | -479.4M | -750.1M | -3.2B | — | — | — | — | — |
| Fin CF | 151.1M | -101.5M | -52.4M | -111.1M | — | — | — | — | — |
Swung more than 81% of stocks we rank over the past year (67% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 688336.SS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 688336.SS | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd(you) | $5.2B | 93 | Strong Buy |
| 9995.HK | RemeGen Co., Ltd. | $5.5B | 94 | Strong Buy |
| 1530.HK | 3SBio Inc. | $5.2B | 97 | Strong Buy |
| 688578.SS | Shanghai Allist Pharmaceuticals Co., Ltd. | $7.0B | 90 | Strong Buy |
| 3759.HK | Pharmaron Beijing Co., Ltd. | $7.1B | 81 | Strong Buy |
| 2315.HK | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | $3.8B | 71 | Buy |
| 300009.SZ | Anhui Anke Biotechnology (Group) Co., Ltd. | $2.1B | 82 | Strong Buy |
| 2142.HK | HBM Holdings Limited | $1.5B | 87 | Strong Buy |
| 6821.HK | Asymchem Laboratories (Tianjin) Co., Ltd. | $6.9B | 66 | Buy |
| 9969.HK | InnoCare Pharma Limited | $3.2B | 66 | Buy |
Peer medians: ROE 4.3% · P/E 27.8x · Gross margin 52.7%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.